Ropivacaine /ml
ApprovedSmall molecule
LundbeckRopivacaine /ml is one of 24 small molecule programs targeting Total Knee Arthroplasty. It is currently in Approved.
1
Indications
6
Total Trials
1
Active Trials
23
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
275 competitors in Total Knee Arthroplasty
#DrugCompanyPhaseTrials
1Ropivacaine /ml
LundbeckApproved
Cymbalta
Alnylam PharmaceuticalsPreclinical
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Xarelto
WWim Janssens
Preclinical
Sufenta
LLeaf Vertical Inc.
Preclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Nucynta
CCollegium Pharmaceutical, Inc.
Preclinical
Epsom Salt
FFresenius Kabi Oncology Ltd.
Preclinical
Zanaflex
LLegacy Health System
Preclinical
Nexium
DDexcel Pharma Technologies Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Bupivacaine1 trial
Post Operative Pain1 trial
Total Knee Arthroplasty1 trial
1 more indication
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ropivacaine /ml. EMBL-EBI & Wellcome Sanger Institute.
- [4]